Johnsfolly

Second project was rust covered deep #8 Wagner skillet. Does have a slight belly and some pitting.

First restoration project,, a Wagner #3. Should be ready to cook with now.

Ok maybe everyone already knew this, but recently had the discussion on what the model number on my cast iron meant. Here's what I found on the internet (from Cast Iron Collector site) - take it with as many grains of salt as you wish . "Regardless of what other markings or logos the major foundries incised into their products, common among nearly all vintage pieces-- whether they be skillets, dutch ovens, waffle irons, or griddles-- are size numbers. Often, the assumption is erroneously made that the large numeral, found normally either on the top of the handle or on the bottom of a piece, indicates its diameter in inches. A measurement of both the top and the bottom rim of a pan, however, will quickly confirm that the number has no direct correlation to either dimension. With the advent of wood-burning stoves, pans were produced to conform to the sizes of the openings in their tops known as "stove eyes". Think of a stove eye as a burner on a modern stove. (Some people still call them that.) A heavy cover piece was left in place when an eye was not directly in use, and removed-- using a special, heat-resistant lifter handle-- when maximum heat from the eye was required. Heat rings, the rims protruding from the bottom circumference of most early cast iron pans, served multiple functions: as a "seal" of sorts between the pan and stove eye, as added stablility for less-than-perfectly flat pan bottoms, and as a device to help reduce hot spots. Depending on the brand of stove, and the sizes of its various eyes, appropriately-sized pans would need to be purchased for use with it. Or, in some cases, the stove maker also produced pans, which they supplied for use with their units. Even after gas-fired ranges-- and, eventually, electric stoves-- became ubiquitous, cast iron cookware continued to be manufactured in the sizes and with the designations originally established for its use on wood-burning stoves. A 1924 Wagner Manufacturing Co. catalog gives these as the bottom diameters of their regular cast iron skillets: #2 - 4-7/8" #3 - 5-1/2" #4 - 5-7/8" #5 - 6-3/4" #6 - 7-1/2" #7 - 8-1/4" #8 - 8-7/8" #9 - 9-3/4" #10 - 10-1/4" #11 - 10-7/8" #12 - 11-3/4" #13 - 12" #14 - 13" These exact dimensions, however, were not standard across all makers. A 1918 Griswold Mfg. Co. catalog lists roughly the same dimensions for its regular skillets, with the #3 and #4 being somewhat smaller than Wagner's, and the #13 and #14 somewhat wider. And a Martin #3 skillet is the same size as a Wagner #2."

I agree. The only advantage to the current situation. If they decide to cancel the season, I wonder how that affect guys that are on the last year of their contracts.

COVID-19 - Thoughts from the Eastern shore.

It's great to have a pond available to you to fish! Congrats on catching some nice looking bass! Sad about the hockey jersey. I don't think that there will a continuation of this year's season . I miss playoff hockey.

Al what is your alternative? Issues with universal/government supported or fully funded health care system can lead to lack of innovations due to limited governmental funds available. The you get what you pay for situation. Currently those countries that have those systems like Canada and the UK benefit from the big pharma generating drugs in a for profit scenario. Ask yourself and maybe do the research on whether your wife would have had the care that she did and the medications/treatments that she used if she were in the UK or Canada? How long would she have had to wait for those treatments? Also would those medications been developed under their system? Maybe they would have, though I tend to doubt it.

I'll throw myself into that camp. I used to think that this was a fishing forum .

As humans we create sport to challenge and push ourselves to overcome those self-imposed obstacles. This is another example. Personally I focus more on catching that species then trying for something different maybe a cherry salmon instead of just a smaller fish of the same species. But those are my self imposed rules😁

Rick most of the anti-vaxxers that I know considered themselves far more educated and intellectual than most. These are people holding multiple degrees and not high school graduates.

For my wife's breakfast Livie and I made scratch drop biscuits. Topped them with sausage gravy and poached eggs.

Nice work! Can't wait to see some action photos!

You sure you didn't mean Bok of your mind ?!?

I found out from an old friend that one of the guys that I went to high school with flew A-10's. I think that @Terrierman mentioned that he would like to know what Harry Reid knows. I am assuming about the UFO videos being released. I can't imagine what folks thought the first time they saw a stealth bomber or our stealth fighters. Probably with the bomber, not much since they were probably being bombed at the time .

The Asian giant hornets found in Washington state that grabbed headlines this week aren’t big killers of humans, although it does happen on rare occasions. But the world's largest hornets do decapitate entire hives of honeybees, and that crucial food pollinator is already in big trouble. Numerous bug experts told The Associated Press that what they call hornet “hype" reminds them of the 1970s public scare when Africanized honeybees, nicknamed “killer bees,” started moving north from South America. While these more aggressive bees did make it up to Texas and the Southwest, they didn’t live up to the horror-movie moniker. However, they also do kill people in rare situations. This time it’s hornets with the homicidal nickname, which bug experts want to ditch. “They are not ‘murder hornets.’ They are just hornets,” said Washington Agriculture Department entomologist Chris Looney, who is working on the state's search for these large hornets. Thank goodness this got cleared up from the hype now I can go back outside

FINALLY for Maryland I no longer have to say that I am keeping darters for dinner! FISHING Effective Thursday, May 7, at 7 a.m, recreational fishing activities, including catch-and-release, are allowed, however: When fishing from a boat, one must be with immediate family members or people with which they reside. No more than 10 people may be on a boat at one time, including captain and crew. When fishing from onshore or at a pier, social distancing guidelines must be followed. DNR fishing piers will reopen immediately. Fishing tournaments remain prohibited at this time. All normal rules and regulations regarding fishing are in effect and must be followed, including creel limits, gear restrictions, and seasons. HUNTING/TRAPPING Effective immediately, all hunting activities are allowed on private and public lands under following conditions: Hunters on public lands must be with immediate family members or people with which they reside. No more than 10 people may be included in a given party. All normal rules and regulations regarding hunting are in effect and must be followed, including bag limits, firearm restrictions, and seasons

Here's the size we have been catching from the shore lines of the rivers around us. Some bigger ones being caught from the beach, but it has been hit or miss and we haven't been able to get to the beaches due to lockdown restrictions.

Great looking fish Jeff! Glad that you were able to guide your friend to some striper success! We haven't seen stripers that size near where we could reach from the shore. I need a boat

It seems to me that is how the French select their meats as well !

Hey we all remember the Devlin McGregor pharmaceuticals and Chicago Memorial hospital cover up with Provasic. If it weren't for Dr. Kimble that would not have been exposed.

That's the way it should be. Naïve to think that it is always the case. I have personal experience of the following: Scientific method = 1. write grant 2. receive grant 3. Conduct experiment. 4. throw out results that don't support proposed work or disprove hypothesis 5. falsify records to support proposed work 6. Write additional grants. 7. Receive tenure/become world expert....

Ok this information is from Wikipedia. So take that with as many grains of salt as you wish. Judy Mikovits – from Wikipedia As research director of a CFS research organization Whittemore Peterson Institute (WPI) from 2006-2011, Mikovits led a research effort that reported in 2009 that a retrovirus known as xenotropic murine leukemia virus-related virus (XMRV) was associated with CFS and may have had a causal role. However, the research came under fire, leading to an eventual retraction on December 22, 2011, by the journal Science. In October 2011, Mikovits was terminated by the WPI for refusing to turn over a cell line that was delivered to her laboratory by mistake, and subsequently came under investigation for alleged manipulation of data in her publications related to XMRV. On November 18, 2011, she was arrested in her Ventura County, California, home and jailed for 5 days. Her lawyer said she was arrested on charges of theft brought by the WPI, but that the charges had no merit. By November 28, after negotiations with the WPI, some lab notes were returned. Later, the criminal charges against her were dismissed by the Reno, Nevada, District Attorney's office Harvey Whittemore and his wife Annette were frustrated by lack of answers for CFS patients, including their daughter. In an effort to solve the CFS problem, they created the Whittemore Peterson Institute in 2005; Mikovits became the research director in 2006. Attempts to find a viral cause of CFS were unsuccessful. In 2007, Mikovits met a co-discoverer of XMRV, Robert Silverman, at a conference. Silverman had found XMRV sequences, which are highly similar to mouse genomic sequences, in prostate cancer specimens several years earlier. Using tools obtained from Silverman, Mikovits began to look for XMRV in her CFS samples. In late 2008, a graduate student, who subsequently was hired as her technician, obtained two positive results from a group of twenty samples. He and Mikovits successively altered the experimental conditions until all samples gave a positive signal. In 2009, Mikovits and co-workers reported in the journal Science that they had detected XMRV DNA in CFS patients and control subjects. Negative results were published soon after, disputing Mikovits's findings. Silverman, who was a co-author of the original XMRV-CFS article, told the Chicago Tribune that he was "concerned about lab contamination, despite our best efforts to avoid it." Two of the original authors of this paper subsequently reanalyzed the samples used in the research and found that the samples were contaminated with XMRV plasmid DNA, leading them to publish a partial retraction of their original results. In December 2011 the editors of Science retracted the paper in its entirety. Mikovits was fired in September 2011 over concerns about her integrity. Lo and Alter, in their 2010 paper titled "Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors", stated "Although we find evidence of a broader group of MLV-related viruses, rather than just XMRV, in patients with CFS and healthy blood donors, our results clearly support the central argument by Lombardi et al. that MLV-related viruses are associated with CFS and are present in some blood donors." This paper was also later retracted by the authors. Mikovits and collaborators went on to participate, alongside two other research groups, in a larger 2012 study with 147 CFS patients and 146 controls. The study concluded that there was no evidence of XMRV or MLV infection in either group, a result that Mikovits said was "the definitive answer" on the issue. Mikovits has become a champion for believers in medical conspiracy theories, basing claims linking the XMRV to autism and cancer on other retracted papers, and claiming she had been jailed by the influence of the Deep state and Big Pharma for exposing the truth about vaccines. In reality, she was arrested on November 18, 2011, for allegedly stealing lab notebooks, a computer, and other material belonging to Whittemore Peterson Institute (WPI). She was held temporarily pursuant to that case. Subsequently, criminal charges brought against Mikovits by Washoe County, Nevada, were dismissed by the District Attorney and Assistant District Attorney in Reno, Nevada. Mikovits has spoken at a number of anti-vaccination events. She has claimed that retroviruses have contaminated 30% of vaccines. Mikovits has garnered criticism from scientists for stating that XMRV is a communicable infection which is "clearly circulating through the population, as is our fear and your fear". Virologist Vincent Racaniello said that Mikovits's assertion "is just inciting fear." Mikovits showed slides at a conference linking XMRV to Parkinson's disease, autism and multiple sclerosis. However, there is no published evidence that XMRV is associated with these diseases. Mikovits has gained attention on social media for promoting her ideas about the 2019–20 coronavirus pandemic. She does not believe that a vaccine is needed to prevent COVID-19, and claims that the coronavirus was "caused by a bad strain of flu vaccine that was circulating between 2013 and 2015". She also claimed masks will “activate” the virus and reinfect a mask-wearer over and over. One of her videos about the coronavirus pandemic was fact-checked by the website Maldita.es, which rated the claims she made as either false or not based in evidence. One such circulating video gained notoriety in May 2020. Titled Plandemic Part 1, this film is a half-hour long documentary-styled interview of Mikovits's perspective on the accusations thrown upon her by the WPI. YouTube has removed this video from its website a number of times, citing community guidelines.

Can't wait for the hot summer months. You can eat those guys right from the road

I have been wondering if they way that they clean those facilities is possibly creating an aerosol containing the virus.

All videos, news articles, public forums, have an agenda. Any where that money is involved there is an agenda either from a personal gain or corporate gain. In regards to financial gains none of us are above reproach. I am always suspect of the narrative of a person that was fired or pushed out as being a means of vindication against those that fired them. However, I do ask myself are there nuggets of truth or ideologies in what was presented that would lead to a cause of concern. In this video, one question that comes up is there a conflict of interest in terms of scientists holding and profiting off of patents while holding administrative responsibilities for a Nationally funded Health organization? Would that person push and fund research on treatments that they profit from? Would a person in that position push out subordinates whose research could shift the treatments from those that this person is profiting from to another treatment pathway. Here's a list of patents that I found in public records for Dr. Fauci. the one that concerns me is patent 6911527, which seems to indicate that he would profit from any vaccine that is prepared using those epitopes and antibodies. Patent number: 9896509 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Publication number: 20160333097 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Patent number: 9441041 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Publication number: 20160075786 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Publication number: 20090285815 Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. Patent number: 7368114 Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins. Patent number: 6911527 Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS. Publication number: 20040265306 Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. Publication number: 20030180254 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Patent number: 6548055 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Patent number: 6190656 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Patent number: 5696079 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy